Pharma Stocks Slide on Us Tariff Threat: Here’s How It Affects You

Mumbai, April 2: Indian pharmaceutical stocks witnessed a sharp sell-off afterreports said that the US may impose up to 100% tariffs on imports of branded and patented drugs.Frontline names like Sun Pharmaceutical Industries and Divi’s Laboratories traded lower by up to 4% in intraday.

The broader impact was even more pronounced, with the Nifty Pharma index declining over 5% and all constituents trading in the red, marking a continuation of sectoral weakness.

At the heart of the sell-off lies a structural concern: the US—the largest export market for Indian pharma—may be turning protectionist in a bid to reshore manufacturing and compress drug prices. While the policy is still evolving, the headline risk is enough to trigger de-rating in stocks with meaningful US exposure.

Here’s a closer look through frequently asked questions or FAQs listed below:

Why Did Pharma Stocks Fall Sharply?

The decline was triggered by reports that the US may impose 100% tariffs on drugmakers that have not agreed to lower prices.

This sparked fears of:

• Margincompression
• Loss of competitiveness in the US market
• Potential disruption to export-driven business models

Which Stocks Were Most Impacted?

Key losers included:

• Sun Pharmaceutical Industries
• Divi’s Laboratories
• Biocon
• Ipca Laboratories
• Torrent Pharmaceuticals

These companies saw declines of up to 4% intraday.

What Exactly is the US Proposing?

The US administration is considering:

• 100% tariffs on imports of branded and patented medicines
• Targeting companies that do not commit to lower drug prices

The policy is aimed at reshoring pharma production and reducing healthcare costs in the US.

Are All Indian Pharma Exports at Risk?

Not immediately. A key nuance:

• Tariffs are primarily aimed at branded and patented drugs
• Generic drugs—which form the bulk of India’s exports—are likely to remain relatively insulated (for now)

However, the market is pricing in policy uncertainty and risk of future expansion of tariffs.

Why Is the US Market So Critical for Indian Pharma?

The US accounts for a significant share of revenue for most Indian pharma companies, especially in generics and speciality drugs.

Any disruption here can impact:

• Revenue growth
• Profit margins
• Valuation multiples

This explains the swift and broad-based market reaction.

What is the Broader Sectoral Impact?

• Nifty Pharma fell over 5%
• The index has now declined for multiple consecutive sessions
• Underperformance versus the broader market has widened

Are Global Pharma Companies Also Affected?

Yes—but selectively. Some global players like Pfizer and Eli Lilly and Company have reportedly secured exemptions or relief by aligning with US pricing and manufacturing expectations.

This creates a two-speed pharma landscape:

• Companies with US alignment are relatively insulated
• Export-heavy, non-aligned players are at risk

What Are the Key Risks Going Forward?

• Expansion of tariffs beyond branded drugs
• Pressure on pricing in the US generics market
• Increased capex requirements for US manufacturing
• Policy unpredictability in global pharma trade

What Should Investors Watch Next?

• Official policy announcement and scope of tariffs
• Exemptions or carve-outs (especially for generics)
• Company-specific exposure to US branded markets
• Strategic responses (for example, US manufacturing plans, partnerships)